Gregg Kokame
Ophthalmology · Aiea, HINPI 1760590988
Payments from drug & device makers
Across 135 payments — averaging $7830.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$701K
- Genentech, Inc.$264K
- Carl Zeiss Meditec, Inc.$43K
- Astellas Pharma Global Development$11K
- F. Hoffmann-la Roche AG$10K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$9K
- plus $19K from 17 others
Across 2 payments — averaging $25,994 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Salutaris Medical Devices, Inc.$51K
- Carl Zeiss Meditec, Inc.$669
What the payments were for
- Consulting fees$27,15337%
- Speaking & faculty fees$7,25010%
- Travel & lodging$4,6826%
- Food & beverage$4,6916%
- Other$29,06740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $701,207 |
| Genentech, Inc. | 40 | $263,789 |
| Carl Zeiss Meditec, Inc. | 9 | $42,794 |
| Astellas Pharma Global Development | 4 | $10,592 |
| F. Hoffmann-la Roche AG | 4 | $9,860 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $9,423 |
| AbbVie(2 entities) | 4 | $8,570 |
| Salutaris Medical Devices, Inc. | 2 | $3,706 |
| Dutch Ophthalmic, USA | 2 | $3,017 |
| Bausch & Lomb Americas Inc. | 5 | $1,487 |
| Genentech USA, Inc. | 17 | $631 |
| Alcon | 6 | $536 |
| Regeneron Healthcare Solutions, Inc. | 4 | $477 |
| Astellas Pharma US Inc | 2 | $203 |
| Alimera Sciences, Inc. | 2 | $188 |
| Hoffmann-la Roche Limited | 2 | $163 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $89 |
| Regeneron | 1 | $85 |
| Biotissue Holdings Inc. | 1 | $50 |
| Aerie Pharmaceuticals, Inc. | 1 | $50 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $37 |
| Glaukos Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS photo$29,067
- CIRRUS HD-OCT$8,643
- VABYSMO$7,271
- VISUDYNE$6,388
- CLARUS$4,135
- CIRRUS 6000$4,000
- LOTEMAX$3,750
- EVA Ophthalmic Surgical System$3,000
- FORUM$2,750
- SMD-Sr90-DA$2,706
- Izervay$374
- EYLEA HD$247
- EYLEA$230
- SUSVIMO$226
- STELLARIS$208
- Unity$140
- Constellation$140
- ARGOS$139
- Iluvien$125
- ACTHAR$125
How this compares
$1,057,095 in reported general payments places this provider in the 95th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 61 | $21,818 |
| Bromfenac Sodium | 98 | $21,103 |
| IlevroNepafenac | 42 | $15,203 |
| Prednisolone Acetate | 117 | $7,779 |
| Brimonidine Tartrate | 32 | $5,208 |
| Timolol Maleate | 31 | $2,550 |
| Brinzolamide | 13 | $2,201 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $789 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $375 |
| Latanoprost | 15 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $9,423 | $21,81861 claims |
| NovartisIlevro | $701,207 | $15,20342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Aiea
- Raymond WeeAiea$2.4M
- James LaiAiea$430K
- Sarah ReadAiea$169K
- William WongAiea$40K
- Luis OmphroyAiea$25K
- Kenneth LeeAiea$3K
- Carlton YuenHonolulu$440K
- Neda NikpoorHonolulu$322K
- Alan FaulknerHonolulu$207K
- Michael BennettHonolulu$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.